3-(3-Chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-7-methoxy-2,1-benzoxazole | 213389-45-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 3-(3-Chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-7-methoxy-2,1-benzoxazole
• CAS: 213389-45-8
• 化学式: C₂₃H₁₇Cl₂NO₄
• 分子量: 442.298
• InChiKey: BJSWGBMLQBHDDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  53.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(3-Chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-7-methoxy-2,1-benzoxazole 在 platinum on activated charcoal 盐酸 、 正丁基锂 、 氯化亚砜 、 三乙基氯硅烷 、 potassium tert-butylate 、 氨 、 氢气 、 三溴化硼 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 生成 7-[Amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-10-(3-chlorophenyl)-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13),10-tetraen-12-one
  参考文献：
  名称：

  5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

  摘要：

  The evaluation of structure activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00180-x
• 作为产物：
  描述：

  2-硝基苯甲醚 在 sodium hydroxide 、 三氯化铝 、 potassium carbonate 、 APTS 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 生成 3-(3-Chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-7-methoxy-2,1-benzoxazole
  参考文献：
  名称：

  5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

  摘要：

  The evaluation of structure activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00180-x

文献信息

• Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
  申请人：——

  公开号：US20020049327A1

  公开（公告）日：2002-04-25

  This invention concerns compounds of formula 1 the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; -A- is a bivalent radical of formula; R 1 and R 2 each independently are hydrogen, hydroxy, halo, cyano, C 1-6 alkyl, trihalomethyl, trihalomethoxy, C 2-6 alkenyl, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, C 1-6 alkyloxyC 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, aminoC 1-6 alkyloxy, mono- or di(C 1-6 alkyl)aminoC 1-6 alkyloxy, Ar, Ar—C 1-6 alkyl, Ar-oxy, Ar—C 1-6 alkyloxy; or when on adjacent positions R 1 and R 2 taken together may form a bivalent radical; R 3 and R 4 each independently are hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 alkyloxy, Ar-oxy, C 1-6 alkylthio, di(C 1-6 alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R 3 and R 4 taken together may form a bivalent radical; R 5 is an imidazolyl substituted with hydrogen or C 1-6 alkyl; R 6 hydrogen, hydroxy, halo, cyano, optionally substituted C 1-6 alkyl, C 1-6 alkyloxycarbonyl or Ar; or a radical of formula —O—R 7 , —S—R 8 , —N—R 8 R 9 ; and Ar is optionally substituted phenyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.

  本发明涉及公式1的化合物及其药物可接受的酸盐和立体化学异构体，其中虚线表示可选键；X是氧或硫；-A-是公式的二价基团；R1和R2各自独立地是氢、羟基、卤、氰、C1-6烷基、三卤甲基、三卤甲氧基、C2-6烯基、C1-6烷氧基、羟基C1-6烷氧基、C1-6烷氧基C1-6烷氧基、C1-6烷氧羰基、氨基C1-6烷氧基、单烷基或二烷基氨基C1-6烷氧基、Ar、Ar-C1-6烷基、Ar-oxy、Ar-C1-6烷氧基；或当相邻位置的R1和R2一起形成二价基团时；R3和R4各自独立地是氢、卤、氰、C1-6烷基、C1-6烷氧基、Ar-oxy、C1-6烷硫基、二(C1-6烷基)氨基、三卤甲基、三卤甲氧基；或当相邻位置的R3和R4一起形成二价基团时；R5是氢或C1-6烷基取代的咪唑基；R6是氢、羟基、卤、氰、可选取代的C1-6烷基、C1-6烷氧羰基或Ar；或公式-O-R7、-S-R8、-N-R8R9的基团；Ar是可选取代的苯基；具有法尼酰转移酶抑制活性；它们的制备、含有它们的组合物以及它们作为药物的用途。
• FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0970079B1

  公开（公告）日：2003-10-01
• US6187786B1
  申请人：——

  公开号：US6187786B1

  公开（公告）日：2001-02-13
• US6444812B1
  申请人：——

  公开号：US6444812B1

  公开（公告）日：2002-09-03
• [EN] FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES<br/>[FR] DERIVES DE QUINOLINONE 1,8-ANNELEE SUBSTITUES PAR DES IMIZADOLES LIES EN N OU EN C INHIBANT LA TRANSEFRASE FARNESYLE
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：WO1998040383A1

  公开（公告）日：1998-09-17

  (EN) This invention concerns compounds of formula (I), the pharmaceutically acceptable acid additions salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; -A- is a bivalent radical of formula; R1 and R2 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar, Ar-C1-6alkyl, Ar-oxy, Ar-C1-6alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical; R3 and R4 each independently are hydrogen, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar-oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy; or when on adjacent positions R3 and R4 taken together may form a bivalent radical; R5 is an imidazolyl substituted with hydrogen or C1-6alkyl; R6 hydrogen, hydroxy, halo, cyano, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl or Ar; or a radical of formula -O-R7, -S-R8, -N-R8R9; and Ar is optionally substituted phenyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.(FR) L'invention concerne des composés de formule (I), leurs sels d'addition acides pharmaceutiquement acceptables et leurs formes stéréo-isomères, où la ligne en pointillé représente une liaison facultative; X désigne oxygène ou soufre; -A- est un radical bivalent de formule; R1 et R2 sont chacun indépendamment hydrogène, hydroxy, halo, cyano, alkyle C1-6, trihalométhyle, trihalométhoxy, alcényle C2-6, alkyloxy C1-6, hydroxyalkyloxy C1-6, alkyloxyC1-6alkyloxy C1-6, alkyloxycarbonyle C1-6, aminoalkyloxy C1-6, mono ou di(alkyle C1-6)amino alkyloxy C1-6, Ar, Ar-alkyle C1-6, Ar-oxy, Ar-alkyloxy C1-6; ou R1-R2, lorsqu'ils sont adjacents et pris ensemble, peuvent former un radical bivalent; R3 et R4 désignent chacun indépendamment hydrogène, halo, cyano, alkyle C1-6, alkyloxy C1-6, Ar-oxy, alkylthio C1-6, di(C1-6alkyl)amino, trihalométhyle, trihalométhoxy; ou R3 et R4, lorsqu'ils sont adjacents et pris ensemble, peuvent former un radical bivalent; R5 est un imidazolyle substitué par un hydrogène ou alkyle C1-6; R6 désigne hydrogène, hydroxy, halo, cyano, éventuellement alkyle C1-6 substitué, alkyloxycarbonyle C1-6 ou Ar; ou un radical de la formule -O-R7, -S-R8, -N-R8R9; et Ar désigne éventuellement phényle substitué. Lesdits composés ont une activité inhibant la transférase farnésyle. L'invention concerne aussi leur préparation, les compositions les contenant et leur utilisation en tant que médicament.